JP4440897B2 - Radiopharmaceutical production system - Google Patents

Description

  The present invention relates to a radiopharmaceutical manufacturing system.

  In the production of radiopharmaceuticals labeled with radioisotopes for use in positron emission tomography (PET), particle accelerators such as cyclotrons are used. The particle accelerator is installed in an accelerator chamber, and RI (Radioisotope) raw material is manufactured in the accelerator chamber. The manufactured RI raw material is sent to a preparation room provided separately, and a radiopharmaceutical such as FDG or methionine is synthesized by a synthesis apparatus installed in the preparation room.

As described above, in the conventional radiopharmaceutical production system, the production of the RI raw material and the production of the radiopharmaceutical are respectively performed in the accelerator chamber and the preparation chamber partitioned by the radiation shielding wall. In order to prevent radiation leakage, the RI raw material, the gas used, and the exhaust gas are transferred through a pipe laid in the underground pit (for example, see Patent Document 1).
JP 2004-353875 A

  However, in the conventional radiopharmaceutical manufacturing system described above, it is necessary to provide an underground pit, so that the construction is troublesome, and the amount of lead used is increased because the pit has a radiation shielding capability, and the manufacturing cost is increased. It was high.

  The present invention has been made in view of the above circumstances, and an object of the present invention is to provide a radiopharmaceutical production system that is easy to construct and can reduce costs.

  The radiopharmaceutical production system according to the present invention is provided with a self-shielding particle accelerator in which a particle accelerator is covered with a first radiation shield, and adjacent to the self-shielding particle accelerator. A synthesis device that synthesizes a radiopharmaceutical using a radioisotope that is coated and manufactured by a particle accelerator, and the first radiation shield within a range where the first radiation shield and the second radiation shield face each other And a second radiation shielding body, and a raw material transfer pipe for transferring the radioisotope from the particle accelerator to the synthesizer.

  In this radiopharmaceutical manufacturing system, the particle accelerator is a self-shielding particle accelerator in which leakage of radiation is suppressed, and a synthesis device covered with a second radiation shield is provided adjacent to the self-shielding particle accelerator. ing. The raw material transfer tube for transferring the radioisotope from the particle accelerator to the synthesizer is within a range where the first radiation shield and the second radiation shield face each other, and the first radiation shield and the second radiation. Connected to the shield. Therefore, it is not necessary to provide an underground pit for the transfer of the radioisotope, and the construction is easy and the cost can be reduced. Further, the system can be made compact by providing the synthesizer and the self-shielding particle accelerator adjacent to each other.

  The radiopharmaceutical manufacturing system is provided adjacent to the self-shielding particle accelerator, is covered with a third radiation shield, and stores waste gas generated by the synthesizer and waste gas from the synthesizer. A waste gas transfer pipe for transferring waste gas to the gas storage device is preferably provided. The waste gas transfer pipe connects the first radiation shield body and the second radiation shield body within a range where the first radiation shield body and the second radiation shield body face each other, and the first radiation shield body It is preferable to connect the first radiation shield and the third radiation shield within a range where the first radiation shield and the third radiation shield face each other. In this way, by effectively using the first radiation shielding body, there is no need to provide an underground pit for transferring waste gas, and the construction is easy and the cost can be further reduced. Become. Further, by providing the waste gas storage device and the self-shielding particle accelerator adjacent to each other, the system can be made more compact.

  The radiopharmaceutical manufacturing system is provided adjacent to the self-shielding particle accelerator, is covered with a third radiation shield, and stores waste gas generated by the synthesizer and waste gas from the synthesizer. A waste gas transfer pipe for transferring waste gas to the gas storage device is preferably provided. The waste gas transfer pipe is preferably connected between the second radiation shield and the third radiation shield within a range where the second radiation shield and the third radiation shield face each other. In this way, it is not necessary to provide an underground pit for transferring the waste gas, and the construction is easy and the cost can be further reduced. Further, by providing the waste gas storage device and the self-shielding particle accelerator adjacent to each other, the system can be made more compact.

  According to the present invention, it is possible to provide a radiopharmaceutical manufacturing system that is easy to construct and can reduce costs.

  Hereinafter, embodiments of the present invention will be described with reference to the accompanying drawings. In the description of the drawings, the same elements are denoted by the same reference numerals, and redundant description is omitted.

  FIG. 1 is a plan view showing a configuration of a radiopharmaceutical manufacturing system according to the present embodiment. The radiopharmaceutical manufacturing system 10 includes a self-shielded cyclotron (self-shielded particle accelerator) 20, a synthesis device 30 accommodated in a hot cell (second radiation shield) 32, and a radiation shield (third radiation shield). ) 42, a waste gas storage device 40 covered with 42. The self-shielded cyclotron 20, the synthesis device 30, and the waste gas storage device 40 are accommodated in a single room surrounded by the radiation shielding wall 50.

  The self-shielded cyclotron 20 is formed by covering a cyclotron 22 with a radiation shield (first radiation shield) 24 installed on the floor. Thus, the “self-shielding type” refers to a type in which the cyclotron 22 is shielded by a wall provided to shield the cyclotron 22 itself, separately from the wall of the building where the cyclotron 22 is installed.

The synthesizer 30 is housed in a hot cell 32 installed on the floor, and synthesizes a radiopharmaceutical using a radioisotope manufactured by the cyclotron 22. For ^{example, 18 O (p, n)} 18 18 were produced by cyclotron 22 by nuclear reaction represented by F F ^- in using a radioisotope represented, ¹⁸ F-FDG as a radiopharmaceutical (fluorodeoxyglucose ).

  The synthesizer 30 is provided adjacent to the self-shielded cyclotron 20. Here, in the form shown in FIG. 1, a partition 52 having a fireproof structure in order to comply with domestic laws and regulations is interposed between the self-shielded cyclotron 20 and the hot cell 32 housing the synthesis apparatus 30. The partition 52 has a thickness of 15 cm or less and is, for example, 10 cm. The partition 52 may be omitted so that the law permits, and the partitions 52 can be arranged so as to be in direct contact with each other.

  The waste gas storage device 40 is provided on the side of the self-shielded cyclotron 20 partitioned by the partition 52, adjacent to the self-shielded cyclotron 20, here in contact with the self-shielded cyclotron 20. The waste gas storage device 40 temporarily stores the waste gas generated in the synthesis device 30 and is covered with a radiation shield 42 installed on the floor.

  Further, the radiopharmaceutical production system 10 includes a raw material transfer pipe 60 that transfers the radioisotope from the cyclotron 22 to the synthesis apparatus 30, and a waste gas transfer pipe 70 that transfers the waste gas from the synthesis apparatus 30 to the waste gas storage apparatus 40. It is equipped with.

  The raw material transfer pipe 60 connects the inside of the radiation shield 24 and the hot cell 32 within a range where the radiation shield 24 covering the cyclotron 22 and the hot cell 32 face each other, and the radioisotope is transmitted from the cyclotron 22 to the synthesizer 30. Transport. Here, “within the range where the radiation shield 24 covering the cyclotron 22 and the hot cell 32 face each other” means the surface facing the hot cell 32 on the radiation shield 24 side and the hot cell 32 side as shown in FIG. A range R in which the radiation shield 24 and the surface facing the radiation shield 24 overlap each other. In this range R, “connecting the inside of the radiation shield 24 and the hot cell 32” means that the raw material transfer pipe 60 does not deviate from the range R in either the width direction or the height direction outside the shield. It means to connect like this.

  The waste gas transfer pipe 70 connects the radiation shield 24 and the hot cell 32 within a range where the radiation shield 24 and the hot cell 32 face each other. The waste gas transfer pipe 70 passes through the radiation shield 24 and within the range where the radiation shield 24 and the radiation shield 42 covering the waste gas storage device 40 face each other. The inside of the shield 42 is connected. In addition, “within the range where the radiation shield 24 and the radiation shield 42 covering the waste gas storage device 40 face each other”, and within this range “connect the radiation shield 24 and the radiation shield 42” , As defined above.

  Here, it is preferable that the portion of the raw material transfer pipe 60 and the waste gas transfer pipe 70 passing through the partition 52 is covered with a shield such as lead in order to prevent radiation leakage.

A quality control device 80 is provided on the side of the synthesis device 30 partitioned by the partition 52 so as to be adjacent to the hot cell 32 of the synthesis device 30. The quality control device 80 is a device that manages the quality of ¹⁸ F-FDG produced as a radioactive chemical solution, and performs a pH test, a purity test, and the like. In addition, an experimental table 82 and a sink 84 are provided on the side of the synthesis device 30 partitioned by the partition 52. This synthesizing device 30 can be accessed through an entrance / exit 86 having an air shower.

  A waste storage 88 is provided on the side of the self-shielded cyclotron 20 partitioned by the partition 52. The self-shielded cyclotron 20 can be accessed through a door 90 having an interlock.

  Next, the operation and effect of the radiopharmaceutical manufacturing system 10 according to the present embodiment will be described.

In this radiopharmaceutical production system 10, a radioisotope represented by ¹⁸ F ⁻ is produced from target water (H ₂ ¹⁸ O) in a cyclotron 22. The produced radioisotope is transferred to the synthesis apparatus 30 through the raw material transfer pipe 60. In the combining device ^{30, 18} F ^- in using a radioisotope represented, ¹⁸ F-FDG as a radiopharmaceutical (fluorodeoxyglucose) is synthesized. A part of the synthesized radiopharmaceutical is sent to the quality control device 80, and a quality test is performed. And a radiopharmaceutical is provided for a test subject by clearing a predetermined condition.

  The activated waste gas generated during the synthesis of the radiopharmaceutical in the synthesizer 30 is transferred to the waste gas storage device 40 through the waste gas transfer pipe 70. And after radioactivity fully attenuate | damps, it is discharge | released from the waste gas storage apparatus 40 to air | atmosphere.

  As described above, in the radiopharmaceutical manufacturing system 10 according to the present embodiment, the cyclotron 22 is the self-shielded cyclotron 10 in which leakage of radiation is suppressed, and the synthesizer 30 accommodated in the hot cell 32 is the self-shielded cyclotron 10. It is provided adjacent to. A raw material transfer pipe 60 for transferring the radioisotope from the cyclotron 22 to the synthesis apparatus 30 connects the radiation shield 24 and the hot cell 32 within a range where the radiation shield 24 and the hot cell 32 face each other. . Therefore, it is not necessary to provide an underground pit for the transfer of the radioisotope, and the construction is easy and the cost can be reduced. Further, the system can be made compact by providing the synthesizing device 30 and the self-shielding cyclotron 20 adjacent to each other.

  As described above, it has been common knowledge that the synthesizer and the cyclotron are accommodated in separate rooms and the radioisotope as a raw material is transferred through the underground pit. However, in this embodiment, the idea is changed and the cyclotron is changed. The self-shielding type with significantly reduced radiation leakage and the cyclotron itself is miniaturized so that the cyclotron and the synthesizer can be integrated into a single radiation shielding room for compactness. ing. And the construction of the underground pit is made unnecessary by connecting the cyclotron and the synthesizer with the raw material transfer pipe.

  Further, the radiopharmaceutical manufacturing system 10 is provided adjacent to the self-shielding cyclotron 20, is covered with a radiation shield 42, and includes a waste gas storage device 40 that stores waste gas generated in the synthesis device 30, and a synthesis. And a waste gas transfer pipe 70 for transferring the waste gas from the device 30 to the waste gas storage device 40. The waste gas transfer pipe 70 connects the radiation shield 24 and the hot cell 32 within a range where the radiation shield 24 and the hot cell 32 face each other, passes through the radiation shield 24, and passes through the radiation shield 24. The radiation shield 24 and the radiation shield 42 are connected within a range where the radiation shield 42 and the radiation shield 42 face each other. Therefore, by effectively using the inside of the radiation shield 24, it is not necessary to provide an underground pit for transferring waste gas, and the construction is easy and the cost can be further reduced. Further, by providing the waste gas storage device 40 and the self-shielded cyclotron 20 adjacent to each other, the system can be made more compact.

The present invention is not limited to the above-described embodiment, and various modifications can be made. For example, in the above-described embodiment, the case where ¹⁸ F-FDG is synthesized as a radiopharmaceutical has been described. However, the radiopharmaceutical is not limited thereto, and ¹³ N-ammonia, ¹¹ C-methionine, or the like may be synthesized.

  In the above-described embodiment, the waste gas transfer pipe 70 connects the radiation shield 24 and the hot cell 32 within a range where the radiation shield 24 and the hot cell 32 face each other, and passes through the radiation shield 24. Thus, the radiation shield 24 and the radiation shield 42 are connected within a range where the radiation shield 24 and the radiation shield 42 face each other. Without being limited thereto, as shown in FIG. 3, the waste gas transfer pipe 70 may connect the hot cell 32 and the radiation shield 42 within a range where the hot cell 32 and the radiation shield 42 face each other. .

  Although the cyclotron has been described as the particle accelerator, other particle accelerators such as a synchrotron may be used in addition to the cyclotron.

It is a top view which shows the structure of the radiopharmaceutical manufacturing system which concerns on embodiment. It is a figure which shows the arrangement | positioning relationship between a self-shielding cyclotron and the synthesis apparatus accommodated in the hot cell. It is a top view which shows the modification of a structure of a radiopharmaceutical manufacturing system.

Explanation of symbols

DESCRIPTION OF SYMBOLS 10 ... Radiopharmaceutical manufacturing system, 20 ... Self-shielded cyclotron, 22 ... Cyclotron, 24 ... Radiation shield, 30 ... Synthesizer, 32 ... Hot cell, 40 ... Waste gas storage device, 42 ... Radiation shield, 60 ... Raw material transfer Pipe, 70 ... Waste gas transfer pipe.

Claims (3)

A self-shielding particle accelerator having a particle accelerator covered with a first radiation shield;
A synthesizer that is provided adjacent to the self-shielding particle accelerator, is coated with a second radiation shield, and synthesizes a radiopharmaceutical using a radioisotope produced by the particle accelerator;
The first radiation shield and the second radiation shield are connected within a range where the first radiation shield and the second radiation shield face each other, and the particle accelerator is transferred to the synthesis device. A raw material transfer pipe for transferring radioisotopes;
A radiopharmaceutical manufacturing system comprising: A waste gas storage device that is provided adjacent to the self-shielding particle accelerator, is covered with a third radiation shield, and stores the waste gas generated in the synthesis device;
A waste gas transfer pipe for transferring waste gas from the synthesis device to the waste gas storage device,
The waste gas transfer pipe connects the first radiation shield and the second radiation shield within a range where the first radiation shield and the second radiation shield face each other, and The first radiation shield and the third radiation shield are connected through the first radiation shield within a range where the first radiation shield and the third radiation shield face each other. The radiopharmaceutical manufacturing system according to claim 1, wherein: A waste gas storage device that is provided adjacent to the self-shielding particle accelerator, is covered with a third radiation shield, and stores the waste gas generated in the synthesis device;
A waste gas transfer pipe for transferring waste gas from the synthesis device to the waste gas storage device,
The waste gas transfer pipe connects the second radiation shield and the third radiation shield within a range where the second radiation shield and the third radiation shield face each other. The radiopharmaceutical manufacturing system according to claim 1.

Images